Treatment of Neurodevelopmental Disorders in Adulthood
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Brain development in neurodevelopmental disorders has been considered to comprise a sequence of critical periods, and abnormalities occurring during early development have been considered irreversible in adulthood. However, findings in mouse models of neurodevelopmental disorders, including fragile X, Rett syndrome, Down syndrome, and neurofibromatosis type I suggest that it is possible to reverse certain molecular, electrophysiological, and behavioral deficits associated with these disorders in adults by genetic or pharmacological manipulations. Furthermore, recent studies have suggested that critical period-like plasticity can be reactivated in the adult brain by environmental manipulations or by pharmacotherapy. These studies open up a tantalizing possibility that targeted pharmacological treatments in combination with regimes of training or rehabilitation might alleviate or reverse the symptoms of neurodevelopmental disorders even after the end of critical developmental periods. Even though translation from animal experimentation to clinical practice is challenging, these results suggest a rational basis for treatment of neurodevelopmental disorders in adulthood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Chondroitinase ABC promotes functional recovery after spinal cord injury
Bradbury, E. J., Moon, L. D. F., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., Fawcett, J. W., & McMahon, S. B. (2002) · Nature · doi:10.1038/416636a · Cited by 2,357 · cited 1×
“Local injections of ChABC promote functional recovery after a spinal cord lesion (Bradbury et al., 2002), and very recent data suggest that a similar kind of plastic state can be achieved with fluoxetine (Scali et al.”
BackgroundCritical period plasticity in local cortical circuits
Hensch, T. K. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1787 · Cited by 2,323 · cited 1×
“Recent studies have shown, using mammalian visual cortex as an experimental model (Berardi et al., 2000; Hensch, 2005), that it is possible to reinstate much greater levels of plasticity in the adult visual cortex than previously suspected, using various environmental and pharmacological strategies (Sale et al.”
BackgroundFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 1×
“FMRP is a regulator of translation for many hundreds of messages from other genes, many of which cause autism when mutated (Darnell et al., 2011).”
BackgroundReactivation of Ocular Dominance Plasticity in the Adult Visual Cortex
Pizzorusso, T., Medini, P., Berardi, N., Chierzi, S., Fawcett, J. W., & Maffei, L. (2002) · Science · doi:10.1126/science.1072699 · Cited by 1,679
Self-citationDe Novo Gene Disruptions in Children on the Autistic Spectrum
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.-H., Narzisi, G., Leotta, A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.04.009 · Cited by 1,446 · cited 5×
“Therefore, reversal of FXS in humans will likely require a combination of targeted treatments because of the multiple pathways that are affected with the loss of FMRP.”
BackgroundInfluentialAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“Studies by Huber and Bear (Huber et al., 2002) first identified up-regulation of the mGluR5 pathway in the FMR1 KO mouse.”
BackgroundNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“Antidepressant drugs have been shown to enhance signs of neuronal plasticity, such as hippocampal neurogenesis and the expression and signaling of BDNF in adult brain (Duman and Monteggia, 2006; Martinowich et al., 2007).”
BackgroundChollet, F., Tardy, J., Albucher, J.-F., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70314-8 · Cited by 925 · cited 1×
“Indeed, fluoxetine has been shown to be effective in the recovery from stroke (Acler et al., 2009; Jorge et al., 2010; Chollet et al., 2011), which might, at least in part, be explained by fluoxetine-induced plasticity and facilitation of the effect of rehabilitation.”
BackgroundThe antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Self-citationZoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797 · cited 2×
“Down syndrome, fragile X syndrome (FXS), Rett syndrome, neurofibromatosis, and tuberous sclerosis are major developmental syndromes leading to intellectual disability (Ehninger et al., 2008; Auerbach et al., 2011; Zoghbi and Bear, 2012), but in the majority of cases, the molecular and neuronal mechanisms underlying th…”
BackgroundJacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 2×
“Preliminary results were positive for fenobam in a single dose in adults with FXS (Berry-Kravis et al., 2009), and for AFQ056 in patients with a fully methylated full mutation (Jacquemont et al., 2011).”
BackgroundSelf-citationRemoving brakes on adult brain plasticity: From molecular to behavioral interventions
Bavelier, D., Levi, D. M., Li, R. W., Dan, Y., & Hensch, T. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4812-10.2010 · Cited by 589
Neuronal Activity-Regulated Gene Transcription in Synapse Development and Cognitive Function
West, A. E., & Greenberg, M. E. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005744 · Cited by 532 · cited 2×
“It has turned out that many of the genes associated with neurodevelopmental disorders play a role in synaptic function (West and Greenberg, 2011; Zoghbi and Bear, 2012), in particular in the regulation of protein synthesis in synapses (Bhakar et al.”
BackgroundSale, A., Maya Vetencourt, J. F., Medini, P., Cenni, M. C., Baroncelli, L., De Pasquale, R., & Maffei, L. (2007) · Nature Neuroscience · doi:10.1038/nn1899 · Cited by 492 · cited 2×
“Furthermore, the exposure of adult rats to EE completely rescued the visual deficits associated with amblyopia (Sale et al., 2007).”
BackgroundSelf-citationChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“For instance, elevation of matrix metalloproteinase 9 has been documented in the FMR1 KO mouse, and treatment with minocycline after birth rescues the immature dendritic spine phenotype and improves the cognitive and behavioral phenotype of the treated mice (Bilousova et al., 2009).”
BackgroundA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 15×
“An additional targeted treatment that lowers glutamate at the synapse through stimulation of GABAB receptors presynaptically, arbaclofen, has also shown benefit in a controlled trial in children and adults with FXS who have autism or significant social deficits (Berry-Kravis et al., in press).”
BackgroundInfluentialSelf-citationFailure of neuronal homeostasis results in common neuropsychiatric phenotypes
Ramocki, M. B., & Zoghbi, H. Y. (2008) · Nature · doi:10.1038/nature07457 · Cited by 399 · cited 1×
“…in several genes associated with neurodevelopmental disorders, both reduced and enhanced expression bring about phenotypes, often with strikingly similar clinical features (Ramocki and Zoghbi, 2008), emphasizing the need for precise maintenance of optimal levels of synaptic regulatory proteins.”
BackgroundFear erasure in mice requires synergy between antidepressant drugs and extinction training
Karpova, N. N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Ágústsdóttir, A., Antila, H., Popova, D., Akamine, Y., Sullivan, R., et al. (2011) · Science · doi:10.1126/science.1214592 · Cited by 382
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370 · cited 1×
“It has turned out that many of the genes associated with neurodevelopmental disorders play a role in synaptic function (West and Greenberg, 2011; Zoghbi and Bear, 2012), in particular in the regulation of protein synthesis in synapses (Bhakar et al., 2012).”
BackgroundStructural and functional recovery from early monocular deprivation in adult rats
Pizzorusso, T., Medini, P., Landi, S., Baldini, S., Berardi, N., & Maffei, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602657103 · Cited by 367
Self-citationLynx1, a Cholinergic Brake, Limits Plasticity in Adult Visual Cortex
Morishita, H., Miwa, J. M., Heintz, N., & Hensch, T. K. (2010) · Science · doi:10.1126/science.1195320 · Cited by 365 · cited 1×
“Furthermore, physostigmine, a cholinesterase inhibitor, was shown to produce similar effects in the mouse visual cortex (Bavelier et al., 2010; Morishita et al., 2010).”
BackgroundEnrich the environment to empower the brain
Sale, A., Berardi, N., & Maffei, L. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.004 · Cited by 341
Self-citationBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Self-citationReducing Intracortical Inhibition in the Adult Visual Cortex Promotes Ocular Dominance Plasticity
Harauzov, A., Spolidoro, M., DiCristo, G., De Pasquale, R., Cancedda, L., Pizzorusso, T., Viegi, A., Berardi, N., & Maffei, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2233-09.2010 · Cited by 319 · cited 1×
“EE effects on adult visual cortex plasticity are likely mediated by an action on intracortical inhibition, a crucial determinant for critical period regulation in the visual system (Harauzov et al., 2010; Sale et al., 2010).”
BackgroundSelf-citationRescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259 · cited 1×
“Targeted treatments in fragile X syndrome: from animal models to humans FXS is an example of how animal models have led to new targeted treatments that appear to be helpful for not only FXS but also for autism spectrum disorders without an FMR1 mutation (Auerbach et al., 2011; Krueger and Bear, 2011).”
BackgroundSilverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251
Long-Term Plasticity of Visually Evoked Potentials in Humans is Altered in Major Depression
Normann, C., Schmitz, D., Fürmaier, A., Döing, C., & Bach, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.006 · Cited by 243
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Studies in patients with FXS demonstrated behavioral benefits in a survey, an open label trial, and a controlled trial of minocycline (Paribello et al., 2010; Utari et al., 2010) (M.”
BackgroundEscitalopram and Enhancement of Cognitive Recovery Following Stroke
Jorge, R. E., Acion, L., Moser, D., Adams, H. P., & Robinson, R. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.185 · Cited by 218 · cited 1×
“Indeed, fluoxetine has been shown to be effective in the recovery from stroke (Acler et al., 2009; Jorge et al., 2010; Chollet et al., 2011), which might, at least in part, be explained by fluoxetine-induced plasticity and facilitation of the effect of rehabilitation.”
BackgroundOpen-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · cited 14×
“An additional targeted treatment that lowers glutamate at the synapse through stimulation of GABAB receptors presynaptically, arbaclofen, has also shown benefit in a controlled trial in children and adults with FXS who have autism or significant social deficits (Berry-Kravis et al., in press).”
BackgroundInfluentialStructural basis for the role of inhibition in facilitating adult brain plasticity
Chen, J. L., Lin, W. C., Cha, J. W., So, P. T., Kubota, Y., & Nedivi, E. (2011) · Nature Neuroscience · doi:10.1038/nn.2799 · Cited by 214 · cited 1×
“An independent study that used two-photon imaging in vivo revealed that fluoxetine treatment induced a simultaneous increase in the extension and retraction of synaptic contacts of inhibitory neurons in adult brain (Chen et al., 2011).”
BackgroundPutignano, E., Lonetti, G., Cancedda, L., Ratto, G., Costa, M., Maffei, L., & Pizzorusso, T. (2007) · Neuron · doi:10.1016/j.neuron.2007.02.007 · Cited by 196 · cited 1×
“Inhibitors of histone deacetylase were shown to induce critical period-like plasticity in the rat visual cortex, indicating that epigenetic regulation of chromatin state plays a role in adult plasticity (Putignano et al., 2007).”
BackgroundSelf-citationReversing Neurodevelopmental Disorders in Adults
Ehninger, D., Li, W., Fox, K., Stryker, M. P., & Silva, A. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.12.007 · Cited by 196 · cited 4×
“Neurodevelopmental disorders first appear during the course of development and maturation, and they are caused by a variety of genetic and environmental conditions (Ehninger et al., 2008).”
BackgroundInfluentialAltered differentiation of neural stem cells in fragile X syndrome
Castrén, M., Tervonen, T., Kärkkäinen, V., Heinonen, S., Castrén, E., Larsson, K., Bakker, C. E., Oostra, B. A., & Åkerman, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508995102 · Cited by 176 · cited 1×
“However, recent studies indicate that the loss of FMRP is associated with deficiencies at multiple developmental stages, including differentiation of human neural stem cells (Castrén et al., 2005; Tervonen et al., 2009; Sheridan et al., 2011).”
BackgroundAcler, M., Robol, E., Fiaschi, A., & Manganotti, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5093-7 · Cited by 139
Vetencourt, J. F. M., Tiraboschi, E., Spolidoro, M., Castrén, E., & Maffei, L. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07488.x · Cited by 138
Self-citationUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · cited 1×
“Studies in patients with FXS demonstrated behavioral benefits in a survey, an open label trial, and a controlled trial of minocycline (Paribello et al., 2010; Utari et al., 2010) (M.”
BackgroundSelf-citationFood restriction enhances visual cortex plasticity in adulthood
Spolidoro, M., Baroncelli, L., Putignano, E., Maya-Vetencourt, J. F., Viegi, A., & Maffei, L. (2011) · Nature Communications · doi:10.1038/ncomms1323 · Cited by 91 · cited 4×
“Fluoxetine-induced adult plasticity correlated with reduction in GABA-mediated inhibition, required the increase expression of BDNF and activation of 5HT1A serotonin receptors (Maya Vetencourt et al., 2008, 2011).”
BackgroundInfluentialSelf-citationAberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome.
Tervonen, T. A., Louhivuori, V., Sun, X., Hokkanen, M.-E., Kratochwil, C. F., Zebryk, P., Castrén, E., & Castrén, M. L. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.010 · Cited by 82 · cited 1×
“However, recent studies indicate that the loss of FMRP is associated with deficiencies at multiple developmental stages, including differentiation of human neural stem cells (Castrén et al., 2005; Tervonen et al., 2009; Sheridan et al., 2011).”
BackgroundBrief Report: Acamprosate in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67
Galuske, R. A. W., Kim, D., Castrén, E., & Singer, W. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00213.x · Cited by 38 · cited 1×
“The first pharmacological treatment that was shown to reactivate critical period-like plasticity in the adult brain was infusion of nerve growth factor (NGF) into the visual cortex of adult cats (Gu et al., 1994; Galuske et al., 2000).”
Background
Cited by
The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
Braat, S., & Kooy, R. F. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.042 · Cited by 294
When pain gets stuck: the evolution of pain chronification and treatment resistance
Borsook, D., Youssef, A. M., Simons, L., Elman, I., & Eccleston, C. (2018) · Pain · doi:10.1097/j.pain.0000000000001401 · Cited by 281
Lessons learned from studying syndromic autism spectrum disorders
Sztainberg, Y., & Zoghbi, H. Y. (2016) · Nature Neuroscience · doi:10.1038/nn.4420 · Cited by 281
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
Deidda, G., Parrini, M., Naskar, S., Bozarth, I. F., Contestabile, A., & Cancedda, L. (2015) · Nature Medicine · doi:10.1038/nm.3827 · Cited by 268
Metadata
- Authors
- Castrén, E., Elgersma, Y., Maffei, L., & Hagerman, R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2012-10-10
- Volume
- 32
- Issue
- 41
- Pages
- 14074-14079
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2138166303
- Cited by
- 63
- References
- 44
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.